Abbott Receives Health Canada Authorization for Whole Blood Rapid Test to Help Assess Suspected Concussions Français

The test, run on Abbott's portable i-STAT ® Alinity ® instrument, uses whole blood to help evaluate patients with a suspected mild traumatic brain injury (mTBI), otherwise known as concussion
The test produces lab-quality results in 15 minutes
Clinicians can get a result at the patient's bedside, making the test accessible at urgent care clinics and healthcare settings outside of the hospital emergency room
The test can be used to help evaluate patients up to 24 hours after injury
MISSISSAUGA, ON, June 16, 2025 /CNW/ -- Abbott (NYSE: ABT) announced today that Health Canada has approved the company's i-STAT TBI test cartridge for use with whole blood, helping clinicians to assess suspected concussion at the patient's bedside and obtain lab-quality results in 15 minutes. Previously, the tests used to help assess mild traumatic brain injury (mTBI) were only authorized for use with plasma or serum, requiring samples to be sent to a lab for processing.
This new authorization will enable testing to be performed in an array of new healthcare settings beyond hospital emergency departments, including urgent care clinics. This is an important step toward a future where testing could be done in settings such as in pharmacies, clinics without radiology or even in locations such as the sidelines of a sporting event.
"Particularly in the emergency setting, we have long needed a reliable and expedient way to assess and triage patients for urgent computed tomography (CT) imaging of the brain after head trauma," said Andrew Beckett, M.D., a trauma surgeon and medical director of the Trauma Program at St. Michael's Hospital, Unity Health Toronto, and an associate professor at the University of Toronto. "The availability of a rapid point of care and objective test for traumatic brain injury will be a major advancement in emergency care as it can help facilitate immediate and precise diagnosis, ensuring prompt, appropriate treatment."
The whole blood test on a portable instrument helps clinicians evaluate patients 18 years of age and older who present with suspected mTBI, commonly known as a concussion. Test results can help rule out the need for a CT scan of the head and assist in determining the best next steps for patient care in conjunction with other clinical information. The ability to perform the test with a whole blood sample means testing can take place in healthcare settings without a lab, which helps to accelerate head trauma evaluation.
With this authorization, the i-STAT TBI test cartridge can be used to help evaluate patients up to 24 hours after injury, an important advancement since those injured often wait to seek care.
It is estimated that 165,000 Canadians will experience a TBI this year. 1 Likewise, each year in Canada, more than 20,000 people are hospitalized for TBI, which can range from mild to severe and include concussions. 2
Among all types of TBIs, concussions are the most common, accounting for approximately 80 to 95 percent of such injuries. 3 Even a mild form of TBI can have long-term consequences. 2
For decades, standard TBI assessment has remained the same, with doctors leveraging tools such as the Canadian CT Head Rule which uses the Glasgow Coma Scale, a subjective assessment as well as CT scans, to detect brain tissue damage or lesions. A blood test provides objective information and helps remove the ambiguity of a standard concussion assessment.
"Abbott has pioneered breakthroughs in TBI testing technology for more than a decade," said Beth McQuiston, M.D., senior medical director in Abbott's diagnostics business. "We're proud of this important step forward in advancing the standard of care for concussions. With this approval, right from the patient's bedside, clinicians are now able to order a rapid blood test that can provide powerful objective information, quickly. This dramatically changes the efficiency in the emergency room and helps optimize patient care."
This approval expands Abbott's TBI test on market offerings, which already includes the i-STAT TBI Plasma test and the ARCHITECT ® and Alinity i lab test (serum and plasma).
How the test works:
The i-STAT TBI test cartridge with the i-STAT Alinity System requires a small venous blood sample – just a few drops applied to the test cartridge. The cartridge is then inserted into the portable i-STAT Alinity instrument. The test measures two brain-specific biomarkers that are released into the blood stream when there is a significant brain injury. If neither of these biomarkers measured are above an established cutoff, a significant injury has likely not occurred, and a CT scan can likely be avoided. Testing for these two biomarkers – ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) – following an injury can provide essential and objective information about a patient's condition and can help healthcare providers decide an appropriate treatment plan.
About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.
The i-STAT TBI test cartridge was developed with support by the U.S. Department of Defense U.S. Army Medical Research and Development Command's (USAMRDC) U.S. Army Medical Materiel Development Activity (USAMMDA). The USAMRDC has been dedicated to developing a solution for the objective detection and evaluation of TBI for more than two decades and has played a critical role in developing the TBI test on Abbott's i-STAT Alinity platform. (Reference to USAMRDC and USAMMDA does not imply or constitute endorsement by these organizations or by the Department of Defense or the U.S. Army.)
The T ransforming R esearch and C linical K nowledge in T raumatic B rain I njury (TRACK-TBI) research team was the first to demonstrate how this TBI blood test can be used for the benefit of TBI patients in clinical care.
1 Brain Injury Canada. Statistics: Traumatic brain injury (TBI) general statistics. Available at https://braininjurycanada.ca/en/statistics/. Accessed on April 29, 2025.
2 Government of Canada. Injury in review, 2020 edition: Spotlight on traumatic brain injuries across the life course. Available at www.canada.ca/en/public-health/services/injury-prevention/canadian-hospitals-injury-reporting-prevention-program/injury-reports/2020-spotlight-traumatic-brain-injuries-life-course.html. Accessed November 2024.
3 Statistics Canada. Self-reported concussions in Canada: A cross-sectional study. Available at https://www150.statcan.gc.ca/n1/pub/82-003-x/2023006/article/00002-eng.htm. Accessed November 2024.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Winnipeg Free Press

2 hours ago

• Winnipeg Free Press

Fading into the background

Opinion The number of people in Canada experiencing homelessness continues to climb despite increased government funding. This prompted dozens of experts from across the country to gather at a landmark forum convened by the Mental Health Commission of Canada (MHCC) to look for answers to help the 34,000 Canadians who — on any given night — don't have a decent place of their own. The main outcome of this gathering, the new report Housing First: What's Next?, released this week, confirms what we've witnessed firsthand: there are proven and effective approaches to end chronic homelessness. The report asserts that Housing First — a Canadian-made strategy that addresses housing insecurity — is a proven method to effectively keep people stably housed over the long term. As a country, how do we stand by as our neighbours cycle through emergency rooms, shelters, and jails? Why do we settle for high-cost band-aid interventions when a permanent fix is already within reach? It's like searching for reading glasses perched on our head. We can't expect people to recover from mental illness or addiction without the dignity of a door that locks. Securing safe, affordable housing is the crucial first step. It's a moral imperative, and fiscally responsible. The principle is straightforward: offer permanent housing in regular units scattered throughout communities — no strings attached — then deliver tailored supports for mental health, substance misuse, employment, and community integration. Rather than requiring people to 'earn' housing through demonstrated 'good behaviour,' Housing First posits – correctly – that a safe place to live is foundational for recovery. Just as we wouldn't expect someone with pneumonia to get better in the rain, we can't expect someone diagnosed with bipolar disorder or schizophrenia to recover while navigating shelter waitlists. We were both heavily involved in At Home/Chez Soi, a federally funded $110 million project launched by the MHCC, which ran from 2008 to 2013. It found that chronic homelessness could be ended permanently for most people by combining housing with portable support. With decades of experience under our belts, our conviction has not wavered. Like the dozens of experts who participated in the workshop that led to the report, we continue to believe Housing First should be adopted and scaled up as best practice. When people have stable housing and access to community supports, we see measurable results: fewer hospitalizations, reduced emergency room visits, and decreased police interactions. These outcomes help offset the cost of implementing Housing First programs. While other countries have embraced this Canadian best practice — Finland and Norway have nearly eliminated chronic homelessness using a Housing First approach — we're still working to fully realize what we ourselves have pioneered. Despite its proven success, implementing Housing First is hard work. It requires carefully coordinating health, housing, justice, and social services that typically operate in silos. It forces us to confront the uncomfortable reality that our housing market has become the privilege of the few, rather than a basic human right. But these challenges can be overcome. During our national forum, experts agreed that an ever-shifting landscape requires an equally nimble response. Our report serves as a call to action and a road map: we need Housing First programs to follow the At Home/Chez Soi model, while upping the ante by collecting better data, creating culturally appropriate supports, establishing improved workforce training, boosting leadership, and increasing public engagement. Creating more deeply affordable housing is also urgent, encouraging private market and not-for-profit landlords to support individuals and families experiencing chronic homelessness — people who are deserving of equitable access to housing opportunities. Taken together, we know this will transform lives. Ironically, when Housing First works well, you don't see it. People integrate into communities as tenants and neighbours, a refreshing contrast to the increasing visibility of suffering on our streets. We can all contribute to meaningful change. By understanding evidence-based approaches and working within our communities to prioritize and implement them, we create pathways to housing stability. Each of us has a role in fostering communities where everyone has a place to call home. Above all, we must never turn away from suffering, especially knowing the proven remedy is in plain sight. Tim Aubry is Emeritus Professor at the University of Ottawa and Co-Chair of the Canadian Housing First Network, and Jino Distasio, is a professor at the University of Winnipeg.

Winnipeg Free Press

2 hours ago

• Winnipeg Free Press

Unlocking ‘gateway benefit'

Opinion Michelle MacIver didn't hear about the many government benefits available for her son, who has a disability, from a financial institution or a family physician. Rather, she heard about them through word of mouth. 'I was talking to other parents who told me about the DTC (Disability Tax Credit),' says the Portage la Prairie mother of two young boys. That began a multi-year journey of navigating doctor's offices, government websites, social media and various organizations to understand not just how to apply for the credit, but also whether her son would even qualify. 'There is a lot of misinformation — like people on social media telling me my son wouldn't qualify,' she says, noting it took two years before she finally sent the 16-page tax document to Canada Revenue Agency. MacIver's glad she did. Not only does the credit provide more than $3,000 in tax savings annually, provincial and federal, it is also the 'gateway benefit,' she says. It leads to other programs aimed at providing financial support for Canadians with disabilities and their families, such as the Registered Disability Savings Plan (RDSP). Those qualifying for the credit will also be eligible for the new Canada Disability Tax Benefit, which starts next month, paying adults with disabilities up to $200 a month, depending on family net income. While that won't help the MacIver family, given her son is nine years old, it will be a small boost to many Canadians with disabilities. The poverty rate for people with disabilities is about twice the national average, according to Campaign 2000: End Child and Family Poverty. What's more, they face larger costs. The cost of living is estimated to be about 30 per cent higher, given many require additional medical equipment and supportive care, a study from Inclusion Canada found. Federal and provincial disability benefit programs are designed to help address these issues, but many are underused, including the gateway tax credit DTC. A Statistics Canada report estimates most Canadians with disabilities have not received the credit. Take-up among those with the most severe impairments is only about four in 10. Use is estimated at about only about 20 per cent for those with severe disabilities, a little more than 10 per cent for Canadian moderate impairments and less than five per cent for people with mild disabilities. These Canadians are not only missing out tax savings; they are forgoing tens of thousands of government monies to help them save for the future through an RDSP. 'It's not being maximized well at all,' says Sara Kinnear, Winnipeg-based director of tax and estate planning at IG Wealth Management. She points to the low take-up of the RDSP, which provides annual grants and bonds to individuals with disabilities age 49 and younger. Statistics Canada data shows the use rate is about 35 per cent. That likely does not reflect the total number of disabled Canadians missing out because the gateway DTC, necessary to open an RDSP, has a much lower take-up rate. One key reason for the low usage is the complexity involved in being approved for the DTC, says Liss Cairns, program manager with the Plan Institute in Vancouver, a non-profit that supports people with disabilities. Applying for the credit is complicated, requiring a health-care provider to fill out and sign the form to confirm an individual's disability. Many physicians now charge fees in the hundreds of dollars to do so, though Cairns adds new federal funding will help cover those costs. Other challenges include public perception, especially for the RDSP. Another issue is awareness even for individuals, who have the DTC and are eligible to open an RDSP. 'Many think, 'What value is this for me? I can't save anything,'' Cairns says. Even individuals who cannot contribute their own money to an RDSP could be missing out. They may be eligible for the Canada disability savings bond whereby the federal government contributes $1,000 annually to their RDSP to a lifetime maximum of $20,000. Of course, individuals and their families able to contribute to an RDSP are eligible for the Canada disability savings grant. A matching grant, it provides up to $3,500 annually from the feds ($3 of benefit for every $1 contributed) to a lifetime maximum of $70,000. Both the bond and grant are pared back gradually as household net income rises. The bond is eliminated when income exceeds about $56,000, and the matching grant is reduced to $1,000 maximum per year when income exceeds about $111,000. 'Overall, it's a great program, but it's also probably the most complicated registered program,' Kinnear says, noting individuals must be wary of early withdrawals for the plan. Money withdrawn from an RDSP within 10 years of the last grant or bond may be subject to steep penalties, she adds. It's also important to start as soon as possible not only because money in the RDSP can compound tax-free. Grants and bonds can only be received up to age 49 though individuals can contribute to their plan up to age 59. 'The design is really to provide retirement savings for these individuals,' Kinnear says, adding all financial institutions can help set up an RDSP. Another resource is the Plan Institute. MacIver leaned on the organization, which provides free assistance, to access the gateway DTC, which allowed her to open the RDSP for her son. Tuesdays A weekly look at politics close to home and around the world. Today, she is a word-of-mouth advocate, helping other parents of children with disabilities. 'Generally, their response is: 'I had no idea this all existed.'' But they're often elated they do exist. If only these many programs were easier to access. 'We know it can be very complex and overwhelming,' Cairns says. 'But we also see the amazing financial empowerment that this can bring.' Joel Schlesinger is a Winnipeg-based freelance journalist joelschles@

Cision Canada

13 hours ago

• Cision Canada

Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference

, June 20, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces that the recently published narrative review titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: has been officially accepted for presentation at PAINWEEK 2025, the national conference on pain management, taking place this September in Las Vegas, Nevada. PAINWEEK is a prestigious event that brings together leading clinicians, researchers, and educators in the field of pain medicine, offering a unique platform to showcase innovative research and best practices. The narrative review, selected through a competitive peer-review process, provides important insights into the potential of synthetic cannabidiol (CBD), administered through extended-release formulations, as a well-tolerated, non-opioid analgesic alternative. Innocan is developing LPT-CBD, an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by multiple animal studies, LPT-CBD has demonstrated steady plasma CBD levels for up to four weeks, prolonged pain relief, and excellent tolerability—offering a promising alternative to current opioid medications and addressing the urgent need to reduce opioid dependency. LPT-CBD will be showcased at the PAINWEEK conference to thousands of healthcare professionals and potential pharmaceutical partners, positioning it at the forefront of groundbreaking non-opioid chronic pain management solutions. "We are honored to be included among the esteemed voices presenting at PAINWEEK this year," said Iris Bincovich, Chief Executive Officer of Innocan."This recognition underscores our commitment to advancing evidence-based pain care and contributing meaningful research to the field." About Innocan: Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales. Contact Information: For Innocan Pharma Corporation: Iris Bincovich, CEO +1 5162104025 +972-54-3012842 +442037699377 [email protected] NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Caution Regarding Forward-Looking Information Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.